Production (Stage)
MBX Biosciences, Inc.
MBX
$11.37
-$0.49-4.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -73.47M | -61.92M | -55.18M | -47.20M | -38.95M |
| Total Depreciation and Amortization | 273.00K | 244.00K | 227.00K | 192.00K | 168.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.78M | 2.40M | 2.79M | 2.77M | 2.35M |
| Change in Net Operating Assets | 4.76M | 4.60M | 2.37M | 1.39M | -528.00K |
| Cash from Operations | -66.65M | -54.68M | -49.79M | -42.85M | -36.96M |
| Capital Expenditure | -631.00K | -874.00K | -837.00K | -802.00K | -381.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -172.17M | -159.72M | -121.37M | -39.22M | -11.78M |
| Cash from Investing | -172.80M | -160.60M | -122.21M | -40.02M | -12.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 174.76M | 174.95M | 174.77M | 275.00K | 859.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 63.50M | 63.50M | 63.50M | 68.51M | 68.51M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.34M | -4.34M | -4.01M | -1.85M | -36.00K |
| Cash from Financing | 233.93M | 234.10M | 234.26M | 66.94M | 69.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.52M | 18.83M | 62.26M | -15.94M | 20.21M |